Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01455090 · ClinicalTrials.gov registry record · Phase 2
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
A Phase 2 study of Chronic Hepatitis C, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT01455090 is a Phase 2 study of Chronic Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 320 participants, above the 194-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT01455090, a Phase 2 study of Chronic Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA \< LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment naive patients, and Genotype (GT1) infected patients who are prior null responders to pegIFN/ribavirin
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG BMS-790052
- DRUG BMS-650032
- DRUG BMS-791325
Study Locations (20)
California
- Southern California Research Center - Coronado
- Peter J Ruane Md Inc - Los Angeles
- Va Greater Los Angeles Healthcare System - Los Angeles
- Research And Education, Inc. - San Diego
- Precision Research Institute, Llc - San Diego
- Medical Associates Research Group - San Diego
Florida
- Orlando Immunology Center - Orlando
- Miami Research Associates - South Miami
Maryland
- Mercy Medical Center, Inc. - Baltimore
- Johns Hopkins University - Lutherville
Oklahoma
- Options Health Research, Llc - Tulsa
- Healthcare Research Consultants - Tulsa
Alabama
- The Kirklin Clinic - Birmingham
Colorado
- University Of Colorado Denver And Hospital - Aurora
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Georgia
- Atlanta Gastroenterology Associates, Llc - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2011-11-30 |
| Est. Completion | 2015-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01455090
The ClinicalTrials.gov registry entry for NCT01455090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 194-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (65% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 4 interventions - of which Ribavirin is the first listed.
NCT01455090 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT01455090 about?
NCT01455090 is a clinical study titled "Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications". The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA \< LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment naive patients, and Genotype (GT1) infected patients who are prior null r...
What is the current status of trial NCT01455090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2011-11-30. Estimated completion is 2015-07-31.
What conditions does trial NCT01455090 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT01455090?
The interventions under investigation include: Ribavirin (DRUG), BMS-790052 (DRUG), BMS-650032 (DRUG), BMS-791325 (DRUG).
Who is sponsoring clinical trial NCT01455090?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01455090 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
COMPLETED · Phase 2
-
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
COMPLETED · Phase 2
-
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
COMPLETED · Phase 2
-
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
COMPLETED · Phase 2
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.